Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.121.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.46NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.44NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CP.1.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FC.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BY.1.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.7.17NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.123 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.27NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.1.71NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.12.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
DN.1.1.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.51NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.17NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.28NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XRNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.350.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.254NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.39.1.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.418NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.9.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.40NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.122NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XAJNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.431NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.168NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Q.6 (Alpha)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AZ.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.97NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.36.18NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.32NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.59NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.67NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBSNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BN.1.2.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XAHNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.2.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBJ.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EP.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.4.1.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CL.1.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBF.8.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XAUNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XAY.1.1.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.25.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XADNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XABNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CH.1.1.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FT.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used